Search the Newsreel

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Samsung Bioepis and Harrow presented positive interim data from a large-scale post-marketing surveillance study on SB11 (BYOOVIZ® / AMELIVU®), a biosimilar to Lucentis, at the ASRS 2026 meeting. The study reinforced the comparable safety profile and demonstrated clinically meaningful efficacy in treatment-naïve patients, while …

Harrow Announces ASRS 2026 Presentation of Studies Supporting IHEEZO and BYOOVIZ in Retina Care

Harrow presented three studies at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting, highlighting clinical evidence for its products IHEEZO, an ocular anesthetic gel, and BYOOVIZ, a biosimilar. Interim findings suggest IHEEZO improves patient experience and does not increase infection risk, with …

Harrow presents studies on eye care products at medical meeting

Harrow Inc. presented three studies on its ophthalmic products, IHEEZO and BYOOVIZ, at a recent medical meeting. The studies highlighted IHEEZO's potential to reduce post-procedure pain and confirmed no increased endophthalmitis risk, while also sharing BYOOVIZ's post-marketing surveillance findings. Despite strong commercial momentum and …

Nearly 20,000 Injections: IHEEZO Finds No Evidence of Added Endophthalmitis Risk

Harrow (Nasdaq: HROW) announced three studies on its retina portfolio products, IHEEZO and BYOOVIZ, at the ASRS 2026 Annual Meeting. An interim study on IHEEZO showed trends toward reduced post-procedure pain and improved patient experience, while a separate real-world analysis of nearly 20,000 injections …

Harrow presents new clinical data supporting IHEEZO and BYOOVIZ at ASRS 2026, boosting confidence in retina treatments.

Harrow, Inc. announced new clinical data at the ASRS 2026 meeting supporting its retina products, IHEEZO and BYOOVIZ. Early trial data for IHEEZO, an ocular anesthetic gel, indicates improved patient comfort and safety during eye injections, with no increased infection risk in real-world data. …

Harrow Among 3 Prime Growth Stocks With Significant Insider Ownership

This article identifies three U.S. growth companies—Harrow (HROW), AvePoint (AVPT), and Peapack-Gladstone Financial (PGC)—that exhibit significant insider ownership, suggesting strong internal confidence. These companies are highlighted for their robust earnings growth forecasts and strategic market positioning, despite the U.S. market remaining flat recently. The …

Harrow stock rises on recent results and market value

Harrow stock is experiencing a rise attributed to its recent operating results and market valuation. The company reported a significant increase in revenue and adjusted EBITDA for 2025, alongside a narrowed net loss and improved adjusted diluted EPS. This performance indicates a business in …

HROW6348836 Bond Profile — Key Metrics

This article provides a detailed profile of the HROW6348836 bond issued by Harrow, Inc. Key metrics include its 8.625% coupon rate, a maturity date of September 15, 2030, a face value of $1,000.00, and a minimum denomination of $2,000.00. Harrow, Inc. is described as …

HROW6348836 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the Harrow, Inc. (HROW6348836 FINRA) 8.625% bond due September 15, 2030. It details the current coupon rate of 8.63% and indicates the next payment is scheduled for September 15, 2026. The page also offers sections for an …

Harrow’s TRIESENCE Phase 3 Milestone Adds New Dimension To Growth Story

Harrow (HROW) Q1 Loss Of US$27.6 Million Rekindles Profitability Concerns

Earnings call transcript: Harrow Health Q1 2026 results miss forecasts, stock drops

Harrow Health earnings missed by $0.39, revenue fell short of estimates

Harrow Health (HROW) Reports Q1 Earnings Miss with Shares Down 9

HARROW HEALTH ($HROW) Releases Q1 2026 Earnings | HROW Stock News

Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for

Harrow Health Prices $50 Million Senior Notes Offering

Harrow Health earnings beat by $0.23, revenue fell short of estimates

Harrow Health Inc (HROW) News, Articles, Events & Latest Updates